強直性脊椎炎治療薬の世界市場成長 2024-2030Global Ankylosing Spondylitis Medication Market Growth 2024-2030 LPI(LPインフォメーション)の最新調査によると、強直性脊椎炎治療薬の世界市場規模は2023年に5億8,690万米ドルとなった。下流市場での需要拡大に伴い、強直性脊椎炎治療薬は2030年までに1億9,960万米ドルの再調... もっと見る
日本語のページは自動翻訳を利用し作成しています。
サマリーLPI(LPインフォメーション)の最新調査によると、強直性脊椎炎治療薬の世界市場規模は2023年に5億8,690万米ドルとなった。下流市場での需要拡大に伴い、強直性脊椎炎治療薬は2030年までに1億9,960万米ドルの再調整規模になると予測され、レビュー期間中のCAGRは9.3%である。この調査レポートは、世界の強直性脊椎炎治療薬市場の成長可能性を明らかにしています。強直性脊椎炎治療薬は今後の市場でも安定した成長が期待される。しかし、強直性脊椎炎治療薬の普及には、製品の差別化、コスト削減、サプライチェーンの最適化が引き続き重要です。市場関係者は、研究開発への投資、戦略的パートナーシップの構築、消費者の嗜好の変化に合わせた製品提供など、強直性脊椎炎治療薬市場がもたらす大きなチャンスを活かす必要がある。 強直性脊椎炎治療薬は、強直性脊椎炎を緩和または治療するために使用される医薬品である。 世界の医薬品市場は、2022年には1475億米ドルとなり、今後6年間のCAGRは5%で成長する。医薬品市場には化学医薬品と生物学的製剤がある。生物製剤は2022年に3810億ドルになると予想されている。これに対し、化学医薬品市場は2018年の1,050億米ドルから2022年には1,090億米ドルに増加すると推定されている。医薬品市場の要因としては、医療需要の増加、技術の進歩、慢性疾患の有病率の上昇、医薬品製造部門の開発に対する民間&政府機関からの資金提供の増加、医薬品の研究開発活動の活発化などが挙げられる。しかし、厳しい規制、研究開発費の高騰、特許切れといった課題にも直面している。企業は、市場での競争力を維持し、必要とする患者に確実に製品を届けるために、継続的に技術革新を行い、こうした課題に適応していく必要がある。さらに、COVID-19の大流行はワクチン開発とサプライチェーン管理の重要性を浮き彫りにし、製薬企業が公衆衛生の新たなニーズに機敏に対応する必要性をさらに強調している。 主な特徴 強直性脊椎炎治療薬市場に関する本レポートは、様々な側面を反映し、業界に関する貴重な洞察を提供します。 市場規模と成長:この調査レポートは、強直性脊椎炎治療薬市場の現在の規模と成長の概要を提供します。過去のデータ、タイプ別(非ステロイド性抗炎症薬(NSAIDs)、副腎皮質ステロイド薬など)の市場区分、地域別内訳などが含まれます。 市場の促進要因と課題:当レポートでは、政府規制、環境問題、技術進歩、消費者の嗜好の変化など、強直性脊椎炎治療薬市場の成長を促進する要因を特定・分析することができます。また、インフラストラクチャーの制限、射程距離への不安、高額な初期費用など、業界が直面する課題も浮き彫りにすることができます。 競合情勢:この調査レポートは、強直性脊椎炎治療薬市場内の競合状況の分析を提供しています。主要企業のプロフィール、市場シェア、戦略、製品提供などが含まれています。また、新興プレーヤーとその潜在的な市場への影響もハイライトできます。 技術開発:調査レポートは、強直性脊椎炎治療薬業界における最新の技術開発について掘り下げることができます。これには、強直性脊椎炎治療薬技術の進歩、強直性脊椎炎治療薬の新規参入、強直性脊椎炎治療薬の新規投資、強直性脊椎炎治療薬の将来を形作るその他の技術革新が含まれます。 川下の事業者の好み:本レポートは、強直性脊椎炎治療薬市場における顧客の購買行動と採用傾向に光を当てることができます。顧客の購買決定、強直性脊椎炎治療薬製品の嗜好に影響を与える要因も含まれる。 政府の政策とインセンティブ調査レポートは、政府の政策とインセンティブが強直性脊椎炎治療薬市場に与える影響を分析します。これには、規制の枠組み、補助金、税制優遇措置、その他強直性脊椎炎治療薬市場の促進を目的とした施策の評価が含まれます。また、市場成長促進におけるこれらの政策の有効性についても評価します。 環境への影響と持続可能性強直性脊椎炎治療薬市場の環境への影響と持続可能性の側面を評価します。 市場予測と将来展望:実施した分析に基づき、調査レポートは強直性脊椎炎治療薬産業の市場予測と展望を提供します。これには、市場規模、成長率、地域別動向、技術進歩や政策展開に関する予測などが含まれます。 提言と機会本レポートは、業界関係者、政策立案者、投資家への提言で締めくくられています。市場関係者が新たなトレンドを活用し、課題を克服し、強直性脊椎炎治療薬市場の成長と発展に貢献するための潜在的な機会を強調しています。 市場の細分化 強直性脊椎炎治療薬市場はタイプ別と用途別に分類される。2019年から2030年までの期間について、セグメント間の成長により、タイプ別、用途別の消費額の正確な計算と予測を数量と金額で提供します。 タイプ別セグメント 非ステロイド性抗炎症薬(NSAIDs) コルチコステロイド 疾患修飾性抗リウマチ薬(DMARDs) 生物学的製剤(TNF遮断薬) スルファサラジン メトトレキサート その他 用途別セグメント 病院 専門クリニック 本レポートは地域別にも市場を分割しています: 南北アメリカ アメリカ カナダ メキシコ ブラジル APAC 中国 日本 韓国 東南アジア インド オーストラリア ヨーロッパ ドイツ フランス 英国 イタリア ロシア 中東・アフリカ エジプト 南アフリカ イスラエル トルコ GCC諸国 以下の企業は、主要な専門家から収集した情報、および企業のカバレッジ、製品ポートフォリオ、市場浸透度の分析に基づいて選択されています。 ファイザー UCBバイオファーマ ヘテロ・バイオファーマ アムジェン カディラ・ファーマシューティカルズ トレント・ファーマシューティカルズ シプラ エムキュア・ファーマシューティカルズ ベーリンガーインゲルハイム 浙江久順製薬 バイオキャド アッヴィ マイセナックス・バイオテック セルトリオン ギリアド・サイエンシズ 江蘇恒瑞医薬有限公司 イザナ・バイオサイエンス 蘇州ゼルジェン・バイオファーマシューティカルズ イルトゥーファーマ キネバントサイエンシズ Qyunsセラピューティクス アケソ・バイオファーマ ニンバス・セラピューティクス エンゼン・バイオサイエンシズ エクスブレイン・バイオファーマ ダイス分子 MSD 本レポートで扱う主な質問 世界の強直性脊椎炎治療薬市場の10年見通しは? 世界および地域別に、強直性脊椎炎治療薬市場の成長を促進する要因は何か? 市場別、地域別に最も急成長する技術は何か? 強直性脊椎炎治療薬の市場機会は最終市場規模によってどのように異なるのか? 強直性脊椎炎治療薬のタイプ別、用途別内訳は? 目次1 Scope of the Report1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global Ankylosing Spondylitis Medication Annual Sales 2019-2030 2.1.2 World Current & Future Analysis for Ankylosing Spondylitis Medication by Geographic Region, 2019, 2023 & 2030 2.1.3 World Current & Future Analysis for Ankylosing Spondylitis Medication by Country/Region, 2019, 2023 & 2030 2.2 Ankylosing Spondylitis Medication Segment by Type 2.2.1 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 2.2.2 Corticosteroids 2.2.3 Disease-Modifying Antirheumatic Drugs (DMARDs) 2.2.4 Biologics (TNF-blocking Agents) 2.2.5 Sulfasalazine 2.2.6 Methotrexate 2.2.7 Others 2.3 Ankylosing Spondylitis Medication Sales by Type 2.3.1 Global Ankylosing Spondylitis Medication Sales Market Share by Type (2019-2024) 2.3.2 Global Ankylosing Spondylitis Medication Revenue and Market Share by Type (2019-2024) 2.3.3 Global Ankylosing Spondylitis Medication Sale Price by Type (2019-2024) 2.4 Ankylosing Spondylitis Medication Segment by Application 2.4.1 Hospital 2.4.2 Specialist Clinic 2.5 Ankylosing Spondylitis Medication Sales by Application 2.5.1 Global Ankylosing Spondylitis Medication Sale Market Share by Application (2019-2024) 2.5.2 Global Ankylosing Spondylitis Medication Revenue and Market Share by Application (2019-2024) 2.5.3 Global Ankylosing Spondylitis Medication Sale Price by Application (2019-2024) 3 Global Ankylosing Spondylitis Medication by Company 3.1 Global Ankylosing Spondylitis Medication Breakdown Data by Company 3.1.1 Global Ankylosing Spondylitis Medication Annual Sales by Company (2019-2024) 3.1.2 Global Ankylosing Spondylitis Medication Sales Market Share by Company (2019-2024) 3.2 Global Ankylosing Spondylitis Medication Annual Revenue by Company (2019-2024) 3.2.1 Global Ankylosing Spondylitis Medication Revenue by Company (2019-2024) 3.2.2 Global Ankylosing Spondylitis Medication Revenue Market Share by Company (2019-2024) 3.3 Global Ankylosing Spondylitis Medication Sale Price by Company 3.4 Key Manufacturers Ankylosing Spondylitis Medication Producing Area Distribution, Sales Area, Product Type 3.4.1 Key Manufacturers Ankylosing Spondylitis Medication Product Location Distribution 3.4.2 Players Ankylosing Spondylitis Medication Products Offered 3.5 Market Concentration Rate Analysis 3.5.1 Competition Landscape Analysis 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024) 3.6 New Products and Potential Entrants 3.7 Mergers & Acquisitions, Expansion 4 World Historic Review for Ankylosing Spondylitis Medication by Geographic Region 4.1 World Historic Ankylosing Spondylitis Medication Market Size by Geographic Region (2019-2024) 4.1.1 Global Ankylosing Spondylitis Medication Annual Sales by Geographic Region (2019-2024) 4.1.2 Global Ankylosing Spondylitis Medication Annual Revenue by Geographic Region (2019-2024) 4.2 World Historic Ankylosing Spondylitis Medication Market Size by Country/Region (2019-2024) 4.2.1 Global Ankylosing Spondylitis Medication Annual Sales by Country/Region (2019-2024) 4.2.2 Global Ankylosing Spondylitis Medication Annual Revenue by Country/Region (2019-2024) 4.3 Americas Ankylosing Spondylitis Medication Sales Growth 4.4 APAC Ankylosing Spondylitis Medication Sales Growth 4.5 Europe Ankylosing Spondylitis Medication Sales Growth 4.6 Middle East & Africa Ankylosing Spondylitis Medication Sales Growth 5 Americas 5.1 Americas Ankylosing Spondylitis Medication Sales by Country 5.1.1 Americas Ankylosing Spondylitis Medication Sales by Country (2019-2024) 5.1.2 Americas Ankylosing Spondylitis Medication Revenue by Country (2019-2024) 5.2 Americas Ankylosing Spondylitis Medication Sales by Type 5.3 Americas Ankylosing Spondylitis Medication Sales by Application 5.4 United States 5.5 Canada 5.6 Mexico 5.7 Brazil 6 APAC 6.1 APAC Ankylosing Spondylitis Medication Sales by Region 6.1.1 APAC Ankylosing Spondylitis Medication Sales by Region (2019-2024) 6.1.2 APAC Ankylosing Spondylitis Medication Revenue by Region (2019-2024) 6.2 APAC Ankylosing Spondylitis Medication Sales by Type 6.3 APAC Ankylosing Spondylitis Medication Sales by Application 6.4 China 6.5 Japan 6.6 South Korea 6.7 Southeast Asia 6.8 India 6.9 Australia 6.10 China Taiwan 7 Europe 7.1 Europe Ankylosing Spondylitis Medication by Country 7.1.1 Europe Ankylosing Spondylitis Medication Sales by Country (2019-2024) 7.1.2 Europe Ankylosing Spondylitis Medication Revenue by Country (2019-2024) 7.2 Europe Ankylosing Spondylitis Medication Sales by Type 7.3 Europe Ankylosing Spondylitis Medication Sales by Application 7.4 Germany 7.5 France 7.6 UK 7.7 Italy 7.8 Russia 8 Middle East & Africa 8.1 Middle East & Africa Ankylosing Spondylitis Medication by Country 8.1.1 Middle East & Africa Ankylosing Spondylitis Medication Sales by Country (2019-2024) 8.1.2 Middle East & Africa Ankylosing Spondylitis Medication Revenue by Country (2019-2024) 8.2 Middle East & Africa Ankylosing Spondylitis Medication Sales by Type 8.3 Middle East & Africa Ankylosing Spondylitis Medication Sales by Application 8.4 Egypt 8.5 South Africa 8.6 Israel 8.7 Turkey 8.8 GCC Countries 9 Market Drivers, Challenges and Trends 9.1 Market Drivers & Growth Opportunities 9.2 Market Challenges & Risks 9.3 Industry Trends 10 Manufacturing Cost Structure Analysis 10.1 Raw Material and Suppliers 10.2 Manufacturing Cost Structure Analysis of Ankylosing Spondylitis Medication 10.3 Manufacturing Process Analysis of Ankylosing Spondylitis Medication 10.4 Industry Chain Structure of Ankylosing Spondylitis Medication 11 Marketing, Distributors and Customer 11.1 Sales Channel 11.1.1 Direct Channels 11.1.2 Indirect Channels 11.2 Ankylosing Spondylitis Medication Distributors 11.3 Ankylosing Spondylitis Medication Customer 12 World Forecast Review for Ankylosing Spondylitis Medication by Geographic Region 12.1 Global Ankylosing Spondylitis Medication Market Size Forecast by Region 12.1.1 Global Ankylosing Spondylitis Medication Forecast by Region (2025-2030) 12.1.2 Global Ankylosing Spondylitis Medication Annual Revenue Forecast by Region (2025-2030) 12.2 Americas Forecast by Country 12.3 APAC Forecast by Region 12.4 Europe Forecast by Country 12.5 Middle East & Africa Forecast by Country 12.6 Global Ankylosing Spondylitis Medication Forecast by Type 12.7 Global Ankylosing Spondylitis Medication Forecast by Application 13 Key Players Analysis 13.1 Pfizer 13.1.1 Pfizer Company Information 13.1.2 Pfizer Ankylosing Spondylitis Medication Product Portfolios and Specifications 13.1.3 Pfizer Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024) 13.1.4 Pfizer Main Business Overview 13.1.5 Pfizer Latest Developments 13.2 UCB Biopharma 13.2.1 UCB Biopharma Company Information 13.2.2 UCB Biopharma Ankylosing Spondylitis Medication Product Portfolios and Specifications 13.2.3 UCB Biopharma Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024) 13.2.4 UCB Biopharma Main Business Overview 13.2.5 UCB Biopharma Latest Developments 13.3 Hetero Biopharma 13.3.1 Hetero Biopharma Company Information 13.3.2 Hetero Biopharma Ankylosing Spondylitis Medication Product Portfolios and Specifications 13.3.3 Hetero Biopharma Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024) 13.3.4 Hetero Biopharma Main Business Overview 13.3.5 Hetero Biopharma Latest Developments 13.4 Amgen 13.4.1 Amgen Company Information 13.4.2 Amgen Ankylosing Spondylitis Medication Product Portfolios and Specifications 13.4.3 Amgen Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024) 13.4.4 Amgen Main Business Overview 13.4.5 Amgen Latest Developments 13.5 Cadila Pharmaceuticals 13.5.1 Cadila Pharmaceuticals Company Information 13.5.2 Cadila Pharmaceuticals Ankylosing Spondylitis Medication Product Portfolios and Specifications 13.5.3 Cadila Pharmaceuticals Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024) 13.5.4 Cadila Pharmaceuticals Main Business Overview 13.5.5 Cadila Pharmaceuticals Latest Developments 13.6 Torrent Pharmaceuticals 13.6.1 Torrent Pharmaceuticals Company Information 13.6.2 Torrent Pharmaceuticals Ankylosing Spondylitis Medication Product Portfolios and Specifications 13.6.3 Torrent Pharmaceuticals Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024) 13.6.4 Torrent Pharmaceuticals Main Business Overview 13.6.5 Torrent Pharmaceuticals Latest Developments 13.7 Cipla 13.7.1 Cipla Company Information 13.7.2 Cipla Ankylosing Spondylitis Medication Product Portfolios and Specifications 13.7.3 Cipla Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024) 13.7.4 Cipla Main Business Overview 13.7.5 Cipla Latest Developments 13.8 Emcure Pharmaceuticals 13.8.1 Emcure Pharmaceuticals Company Information 13.8.2 Emcure Pharmaceuticals Ankylosing Spondylitis Medication Product Portfolios and Specifications 13.8.3 Emcure Pharmaceuticals Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024) 13.8.4 Emcure Pharmaceuticals Main Business Overview 13.8.5 Emcure Pharmaceuticals Latest Developments 13.9 Boehringer Ingelheim 13.9.1 Boehringer Ingelheim Company Information 13.9.2 Boehringer Ingelheim Ankylosing Spondylitis Medication Product Portfolios and Specifications 13.9.3 Boehringer Ingelheim Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024) 13.9.4 Boehringer Ingelheim Main Business Overview 13.9.5 Boehringer Ingelheim Latest Developments 13.10 Zhejiang Hisun Pharmaceuticals 13.10.1 Zhejiang Hisun Pharmaceuticals Company Information 13.10.2 Zhejiang Hisun Pharmaceuticals Ankylosing Spondylitis Medication Product Portfolios and Specifications 13.10.3 Zhejiang Hisun Pharmaceuticals Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024) 13.10.4 Zhejiang Hisun Pharmaceuticals Main Business Overview 13.10.5 Zhejiang Hisun Pharmaceuticals Latest Developments 13.11 Biocad 13.11.1 Biocad Company Information 13.11.2 Biocad Ankylosing Spondylitis Medication Product Portfolios and Specifications 13.11.3 Biocad Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024) 13.11.4 Biocad Main Business Overview 13.11.5 Biocad Latest Developments 13.12 AbbVie 13.12.1 AbbVie Company Information 13.12.2 AbbVie Ankylosing Spondylitis Medication Product Portfolios and Specifications 13.12.3 AbbVie Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024) 13.12.4 AbbVie Main Business Overview 13.12.5 AbbVie Latest Developments 13.13 Mycenax Biotech 13.13.1 Mycenax Biotech Company Information 13.13.2 Mycenax Biotech Ankylosing Spondylitis Medication Product Portfolios and Specifications 13.13.3 Mycenax Biotech Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024) 13.13.4 Mycenax Biotech Main Business Overview 13.13.5 Mycenax Biotech Latest Developments 13.14 Celltrion 13.14.1 Celltrion Company Information 13.14.2 Celltrion Ankylosing Spondylitis Medication Product Portfolios and Specifications 13.14.3 Celltrion Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024) 13.14.4 Celltrion Main Business Overview 13.14.5 Celltrion Latest Developments 13.15 Gilead Sciences 13.15.1 Gilead Sciences Company Information 13.15.2 Gilead Sciences Ankylosing Spondylitis Medication Product Portfolios and Specifications 13.15.3 Gilead Sciences Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024) 13.15.4 Gilead Sciences Main Business Overview 13.15.5 Gilead Sciences Latest Developments 13.16 Jiangsu HengRui Medicine Co., Ltd. 13.16.1 Jiangsu HengRui Medicine Co., Ltd. Company Information 13.16.2 Jiangsu HengRui Medicine Co., Ltd. Ankylosing Spondylitis Medication Product Portfolios and Specifications 13.16.3 Jiangsu HengRui Medicine Co., Ltd. Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024) 13.16.4 Jiangsu HengRui Medicine Co., Ltd. Main Business Overview 13.16.5 Jiangsu HengRui Medicine Co., Ltd. Latest Developments 13.17 Izana Bioscience 13.17.1 Izana Bioscience Company Information 13.17.2 Izana Bioscience Ankylosing Spondylitis Medication Product Portfolios and Specifications 13.17.3 Izana Bioscience Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024) 13.17.4 Izana Bioscience Main Business Overview 13.17.5 Izana Bioscience Latest Developments 13.18 Suzhou Zelgen Biopharmaceuticals 13.18.1 Suzhou Zelgen Biopharmaceuticals Company Information 13.18.2 Suzhou Zelgen Biopharmaceuticals Ankylosing Spondylitis Medication Product Portfolios and Specifications 13.18.3 Suzhou Zelgen Biopharmaceuticals Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024) 13.18.4 Suzhou Zelgen Biopharmaceuticals Main Business Overview 13.18.5 Suzhou Zelgen Biopharmaceuticals Latest Developments 13.19 Iltoo Pharma 13.19.1 Iltoo Pharma Company Information 13.19.2 Iltoo Pharma Ankylosing Spondylitis Medication Product Portfolios and Specifications 13.19.3 Iltoo Pharma Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024) 13.19.4 Iltoo Pharma Main Business Overview 13.19.5 Iltoo Pharma Latest Developments 13.20 Kinevant Sciences 13.20.1 Kinevant Sciences Company Information 13.20.2 Kinevant Sciences Ankylosing Spondylitis Medication Product Portfolios and Specifications 13.20.3 Kinevant Sciences Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024) 13.20.4 Kinevant Sciences Main Business Overview 13.20.5 Kinevant Sciences Latest Developments 13.21 Qyuns Therapeutics 13.21.1 Qyuns Therapeutics Company Information 13.21.2 Qyuns Therapeutics Ankylosing Spondylitis Medication Product Portfolios and Specifications 13.21.3 Qyuns Therapeutics Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024) 13.21.4 Qyuns Therapeutics Main Business Overview 13.21.5 Qyuns Therapeutics Latest Developments 13.22 Akeso Biopharma 13.22.1 Akeso Biopharma Company Information 13.22.2 Akeso Biopharma Ankylosing Spondylitis Medication Product Portfolios and Specifications 13.22.3 Akeso Biopharma Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024) 13.22.4 Akeso Biopharma Main Business Overview 13.22.5 Akeso Biopharma Latest Developments 13.23 Nimbus Therapeutics 13.23.1 Nimbus Therapeutics Company Information 13.23.2 Nimbus Therapeutics Ankylosing Spondylitis Medication Product Portfolios and Specifications 13.23.3 Nimbus Therapeutics Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024) 13.23.4 Nimbus Therapeutics Main Business Overview 13.23.5 Nimbus Therapeutics Latest Developments 13.24 Enzene Biosciences 13.24.1 Enzene Biosciences Company Information 13.24.2 Enzene Biosciences Ankylosing Spondylitis Medication Product Portfolios and Specifications 13.24.3 Enzene Biosciences Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024) 13.24.4 Enzene Biosciences Main Business Overview 13.24.5 Enzene Biosciences Latest Developments 13.25 Xbrane Biopharma 13.25.1 Xbrane Biopharma Company Information 13.25.2 Xbrane Biopharma Ankylosing Spondylitis Medication Product Portfolios and Specifications 13.25.3 Xbrane Biopharma Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024) 13.25.4 Xbrane Biopharma Main Business Overview 13.25.5 Xbrane Biopharma Latest Developments 13.26 Dice molecules 13.26.1 Dice molecules Company Information 13.26.2 Dice molecules Ankylosing Spondylitis Medication Product Portfolios and Specifications 13.26.3 Dice molecules Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024) 13.26.4 Dice molecules Main Business Overview 13.26.5 Dice molecules Latest Developments 13.27 MSD 13.27.1 MSD Company Information 13.27.2 MSD Ankylosing Spondylitis Medication Product Portfolios and Specifications 13.27.3 MSD Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024) 13.27.4 MSD Main Business Overview 13.27.5 MSD Latest Developments 14 Research Findings and Conclusion
SummaryAccording to our LPI (LP Information) latest study, the global Ankylosing Spondylitis Medication market size was valued at US$ 5869.5 million in 2023. With growing demand in downstream market, the Ankylosing Spondylitis Medication is forecast to a readjusted size of US$ 10960 million by 2030 with a CAGR of 9.3% during review period. Table of Contents1 Scope of the Report1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global Ankylosing Spondylitis Medication Annual Sales 2019-2030 2.1.2 World Current & Future Analysis for Ankylosing Spondylitis Medication by Geographic Region, 2019, 2023 & 2030 2.1.3 World Current & Future Analysis for Ankylosing Spondylitis Medication by Country/Region, 2019, 2023 & 2030 2.2 Ankylosing Spondylitis Medication Segment by Type 2.2.1 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 2.2.2 Corticosteroids 2.2.3 Disease-Modifying Antirheumatic Drugs (DMARDs) 2.2.4 Biologics (TNF-blocking Agents) 2.2.5 Sulfasalazine 2.2.6 Methotrexate 2.2.7 Others 2.3 Ankylosing Spondylitis Medication Sales by Type 2.3.1 Global Ankylosing Spondylitis Medication Sales Market Share by Type (2019-2024) 2.3.2 Global Ankylosing Spondylitis Medication Revenue and Market Share by Type (2019-2024) 2.3.3 Global Ankylosing Spondylitis Medication Sale Price by Type (2019-2024) 2.4 Ankylosing Spondylitis Medication Segment by Application 2.4.1 Hospital 2.4.2 Specialist Clinic 2.5 Ankylosing Spondylitis Medication Sales by Application 2.5.1 Global Ankylosing Spondylitis Medication Sale Market Share by Application (2019-2024) 2.5.2 Global Ankylosing Spondylitis Medication Revenue and Market Share by Application (2019-2024) 2.5.3 Global Ankylosing Spondylitis Medication Sale Price by Application (2019-2024) 3 Global Ankylosing Spondylitis Medication by Company 3.1 Global Ankylosing Spondylitis Medication Breakdown Data by Company 3.1.1 Global Ankylosing Spondylitis Medication Annual Sales by Company (2019-2024) 3.1.2 Global Ankylosing Spondylitis Medication Sales Market Share by Company (2019-2024) 3.2 Global Ankylosing Spondylitis Medication Annual Revenue by Company (2019-2024) 3.2.1 Global Ankylosing Spondylitis Medication Revenue by Company (2019-2024) 3.2.2 Global Ankylosing Spondylitis Medication Revenue Market Share by Company (2019-2024) 3.3 Global Ankylosing Spondylitis Medication Sale Price by Company 3.4 Key Manufacturers Ankylosing Spondylitis Medication Producing Area Distribution, Sales Area, Product Type 3.4.1 Key Manufacturers Ankylosing Spondylitis Medication Product Location Distribution 3.4.2 Players Ankylosing Spondylitis Medication Products Offered 3.5 Market Concentration Rate Analysis 3.5.1 Competition Landscape Analysis 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024) 3.6 New Products and Potential Entrants 3.7 Mergers & Acquisitions, Expansion 4 World Historic Review for Ankylosing Spondylitis Medication by Geographic Region 4.1 World Historic Ankylosing Spondylitis Medication Market Size by Geographic Region (2019-2024) 4.1.1 Global Ankylosing Spondylitis Medication Annual Sales by Geographic Region (2019-2024) 4.1.2 Global Ankylosing Spondylitis Medication Annual Revenue by Geographic Region (2019-2024) 4.2 World Historic Ankylosing Spondylitis Medication Market Size by Country/Region (2019-2024) 4.2.1 Global Ankylosing Spondylitis Medication Annual Sales by Country/Region (2019-2024) 4.2.2 Global Ankylosing Spondylitis Medication Annual Revenue by Country/Region (2019-2024) 4.3 Americas Ankylosing Spondylitis Medication Sales Growth 4.4 APAC Ankylosing Spondylitis Medication Sales Growth 4.5 Europe Ankylosing Spondylitis Medication Sales Growth 4.6 Middle East & Africa Ankylosing Spondylitis Medication Sales Growth 5 Americas 5.1 Americas Ankylosing Spondylitis Medication Sales by Country 5.1.1 Americas Ankylosing Spondylitis Medication Sales by Country (2019-2024) 5.1.2 Americas Ankylosing Spondylitis Medication Revenue by Country (2019-2024) 5.2 Americas Ankylosing Spondylitis Medication Sales by Type 5.3 Americas Ankylosing Spondylitis Medication Sales by Application 5.4 United States 5.5 Canada 5.6 Mexico 5.7 Brazil 6 APAC 6.1 APAC Ankylosing Spondylitis Medication Sales by Region 6.1.1 APAC Ankylosing Spondylitis Medication Sales by Region (2019-2024) 6.1.2 APAC Ankylosing Spondylitis Medication Revenue by Region (2019-2024) 6.2 APAC Ankylosing Spondylitis Medication Sales by Type 6.3 APAC Ankylosing Spondylitis Medication Sales by Application 6.4 China 6.5 Japan 6.6 South Korea 6.7 Southeast Asia 6.8 India 6.9 Australia 6.10 China Taiwan 7 Europe 7.1 Europe Ankylosing Spondylitis Medication by Country 7.1.1 Europe Ankylosing Spondylitis Medication Sales by Country (2019-2024) 7.1.2 Europe Ankylosing Spondylitis Medication Revenue by Country (2019-2024) 7.2 Europe Ankylosing Spondylitis Medication Sales by Type 7.3 Europe Ankylosing Spondylitis Medication Sales by Application 7.4 Germany 7.5 France 7.6 UK 7.7 Italy 7.8 Russia 8 Middle East & Africa 8.1 Middle East & Africa Ankylosing Spondylitis Medication by Country 8.1.1 Middle East & Africa Ankylosing Spondylitis Medication Sales by Country (2019-2024) 8.1.2 Middle East & Africa Ankylosing Spondylitis Medication Revenue by Country (2019-2024) 8.2 Middle East & Africa Ankylosing Spondylitis Medication Sales by Type 8.3 Middle East & Africa Ankylosing Spondylitis Medication Sales by Application 8.4 Egypt 8.5 South Africa 8.6 Israel 8.7 Turkey 8.8 GCC Countries 9 Market Drivers, Challenges and Trends 9.1 Market Drivers & Growth Opportunities 9.2 Market Challenges & Risks 9.3 Industry Trends 10 Manufacturing Cost Structure Analysis 10.1 Raw Material and Suppliers 10.2 Manufacturing Cost Structure Analysis of Ankylosing Spondylitis Medication 10.3 Manufacturing Process Analysis of Ankylosing Spondylitis Medication 10.4 Industry Chain Structure of Ankylosing Spondylitis Medication 11 Marketing, Distributors and Customer 11.1 Sales Channel 11.1.1 Direct Channels 11.1.2 Indirect Channels 11.2 Ankylosing Spondylitis Medication Distributors 11.3 Ankylosing Spondylitis Medication Customer 12 World Forecast Review for Ankylosing Spondylitis Medication by Geographic Region 12.1 Global Ankylosing Spondylitis Medication Market Size Forecast by Region 12.1.1 Global Ankylosing Spondylitis Medication Forecast by Region (2025-2030) 12.1.2 Global Ankylosing Spondylitis Medication Annual Revenue Forecast by Region (2025-2030) 12.2 Americas Forecast by Country 12.3 APAC Forecast by Region 12.4 Europe Forecast by Country 12.5 Middle East & Africa Forecast by Country 12.6 Global Ankylosing Spondylitis Medication Forecast by Type 12.7 Global Ankylosing Spondylitis Medication Forecast by Application 13 Key Players Analysis 13.1 Pfizer 13.1.1 Pfizer Company Information 13.1.2 Pfizer Ankylosing Spondylitis Medication Product Portfolios and Specifications 13.1.3 Pfizer Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024) 13.1.4 Pfizer Main Business Overview 13.1.5 Pfizer Latest Developments 13.2 UCB Biopharma 13.2.1 UCB Biopharma Company Information 13.2.2 UCB Biopharma Ankylosing Spondylitis Medication Product Portfolios and Specifications 13.2.3 UCB Biopharma Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024) 13.2.4 UCB Biopharma Main Business Overview 13.2.5 UCB Biopharma Latest Developments 13.3 Hetero Biopharma 13.3.1 Hetero Biopharma Company Information 13.3.2 Hetero Biopharma Ankylosing Spondylitis Medication Product Portfolios and Specifications 13.3.3 Hetero Biopharma Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024) 13.3.4 Hetero Biopharma Main Business Overview 13.3.5 Hetero Biopharma Latest Developments 13.4 Amgen 13.4.1 Amgen Company Information 13.4.2 Amgen Ankylosing Spondylitis Medication Product Portfolios and Specifications 13.4.3 Amgen Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024) 13.4.4 Amgen Main Business Overview 13.4.5 Amgen Latest Developments 13.5 Cadila Pharmaceuticals 13.5.1 Cadila Pharmaceuticals Company Information 13.5.2 Cadila Pharmaceuticals Ankylosing Spondylitis Medication Product Portfolios and Specifications 13.5.3 Cadila Pharmaceuticals Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024) 13.5.4 Cadila Pharmaceuticals Main Business Overview 13.5.5 Cadila Pharmaceuticals Latest Developments 13.6 Torrent Pharmaceuticals 13.6.1 Torrent Pharmaceuticals Company Information 13.6.2 Torrent Pharmaceuticals Ankylosing Spondylitis Medication Product Portfolios and Specifications 13.6.3 Torrent Pharmaceuticals Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024) 13.6.4 Torrent Pharmaceuticals Main Business Overview 13.6.5 Torrent Pharmaceuticals Latest Developments 13.7 Cipla 13.7.1 Cipla Company Information 13.7.2 Cipla Ankylosing Spondylitis Medication Product Portfolios and Specifications 13.7.3 Cipla Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024) 13.7.4 Cipla Main Business Overview 13.7.5 Cipla Latest Developments 13.8 Emcure Pharmaceuticals 13.8.1 Emcure Pharmaceuticals Company Information 13.8.2 Emcure Pharmaceuticals Ankylosing Spondylitis Medication Product Portfolios and Specifications 13.8.3 Emcure Pharmaceuticals Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024) 13.8.4 Emcure Pharmaceuticals Main Business Overview 13.8.5 Emcure Pharmaceuticals Latest Developments 13.9 Boehringer Ingelheim 13.9.1 Boehringer Ingelheim Company Information 13.9.2 Boehringer Ingelheim Ankylosing Spondylitis Medication Product Portfolios and Specifications 13.9.3 Boehringer Ingelheim Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024) 13.9.4 Boehringer Ingelheim Main Business Overview 13.9.5 Boehringer Ingelheim Latest Developments 13.10 Zhejiang Hisun Pharmaceuticals 13.10.1 Zhejiang Hisun Pharmaceuticals Company Information 13.10.2 Zhejiang Hisun Pharmaceuticals Ankylosing Spondylitis Medication Product Portfolios and Specifications 13.10.3 Zhejiang Hisun Pharmaceuticals Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024) 13.10.4 Zhejiang Hisun Pharmaceuticals Main Business Overview 13.10.5 Zhejiang Hisun Pharmaceuticals Latest Developments 13.11 Biocad 13.11.1 Biocad Company Information 13.11.2 Biocad Ankylosing Spondylitis Medication Product Portfolios and Specifications 13.11.3 Biocad Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024) 13.11.4 Biocad Main Business Overview 13.11.5 Biocad Latest Developments 13.12 AbbVie 13.12.1 AbbVie Company Information 13.12.2 AbbVie Ankylosing Spondylitis Medication Product Portfolios and Specifications 13.12.3 AbbVie Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024) 13.12.4 AbbVie Main Business Overview 13.12.5 AbbVie Latest Developments 13.13 Mycenax Biotech 13.13.1 Mycenax Biotech Company Information 13.13.2 Mycenax Biotech Ankylosing Spondylitis Medication Product Portfolios and Specifications 13.13.3 Mycenax Biotech Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024) 13.13.4 Mycenax Biotech Main Business Overview 13.13.5 Mycenax Biotech Latest Developments 13.14 Celltrion 13.14.1 Celltrion Company Information 13.14.2 Celltrion Ankylosing Spondylitis Medication Product Portfolios and Specifications 13.14.3 Celltrion Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024) 13.14.4 Celltrion Main Business Overview 13.14.5 Celltrion Latest Developments 13.15 Gilead Sciences 13.15.1 Gilead Sciences Company Information 13.15.2 Gilead Sciences Ankylosing Spondylitis Medication Product Portfolios and Specifications 13.15.3 Gilead Sciences Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024) 13.15.4 Gilead Sciences Main Business Overview 13.15.5 Gilead Sciences Latest Developments 13.16 Jiangsu HengRui Medicine Co., Ltd. 13.16.1 Jiangsu HengRui Medicine Co., Ltd. Company Information 13.16.2 Jiangsu HengRui Medicine Co., Ltd. Ankylosing Spondylitis Medication Product Portfolios and Specifications 13.16.3 Jiangsu HengRui Medicine Co., Ltd. Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024) 13.16.4 Jiangsu HengRui Medicine Co., Ltd. Main Business Overview 13.16.5 Jiangsu HengRui Medicine Co., Ltd. Latest Developments 13.17 Izana Bioscience 13.17.1 Izana Bioscience Company Information 13.17.2 Izana Bioscience Ankylosing Spondylitis Medication Product Portfolios and Specifications 13.17.3 Izana Bioscience Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024) 13.17.4 Izana Bioscience Main Business Overview 13.17.5 Izana Bioscience Latest Developments 13.18 Suzhou Zelgen Biopharmaceuticals 13.18.1 Suzhou Zelgen Biopharmaceuticals Company Information 13.18.2 Suzhou Zelgen Biopharmaceuticals Ankylosing Spondylitis Medication Product Portfolios and Specifications 13.18.3 Suzhou Zelgen Biopharmaceuticals Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024) 13.18.4 Suzhou Zelgen Biopharmaceuticals Main Business Overview 13.18.5 Suzhou Zelgen Biopharmaceuticals Latest Developments 13.19 Iltoo Pharma 13.19.1 Iltoo Pharma Company Information 13.19.2 Iltoo Pharma Ankylosing Spondylitis Medication Product Portfolios and Specifications 13.19.3 Iltoo Pharma Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024) 13.19.4 Iltoo Pharma Main Business Overview 13.19.5 Iltoo Pharma Latest Developments 13.20 Kinevant Sciences 13.20.1 Kinevant Sciences Company Information 13.20.2 Kinevant Sciences Ankylosing Spondylitis Medication Product Portfolios and Specifications 13.20.3 Kinevant Sciences Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024) 13.20.4 Kinevant Sciences Main Business Overview 13.20.5 Kinevant Sciences Latest Developments 13.21 Qyuns Therapeutics 13.21.1 Qyuns Therapeutics Company Information 13.21.2 Qyuns Therapeutics Ankylosing Spondylitis Medication Product Portfolios and Specifications 13.21.3 Qyuns Therapeutics Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024) 13.21.4 Qyuns Therapeutics Main Business Overview 13.21.5 Qyuns Therapeutics Latest Developments 13.22 Akeso Biopharma 13.22.1 Akeso Biopharma Company Information 13.22.2 Akeso Biopharma Ankylosing Spondylitis Medication Product Portfolios and Specifications 13.22.3 Akeso Biopharma Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024) 13.22.4 Akeso Biopharma Main Business Overview 13.22.5 Akeso Biopharma Latest Developments 13.23 Nimbus Therapeutics 13.23.1 Nimbus Therapeutics Company Information 13.23.2 Nimbus Therapeutics Ankylosing Spondylitis Medication Product Portfolios and Specifications 13.23.3 Nimbus Therapeutics Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024) 13.23.4 Nimbus Therapeutics Main Business Overview 13.23.5 Nimbus Therapeutics Latest Developments 13.24 Enzene Biosciences 13.24.1 Enzene Biosciences Company Information 13.24.2 Enzene Biosciences Ankylosing Spondylitis Medication Product Portfolios and Specifications 13.24.3 Enzene Biosciences Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024) 13.24.4 Enzene Biosciences Main Business Overview 13.24.5 Enzene Biosciences Latest Developments 13.25 Xbrane Biopharma 13.25.1 Xbrane Biopharma Company Information 13.25.2 Xbrane Biopharma Ankylosing Spondylitis Medication Product Portfolios and Specifications 13.25.3 Xbrane Biopharma Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024) 13.25.4 Xbrane Biopharma Main Business Overview 13.25.5 Xbrane Biopharma Latest Developments 13.26 Dice molecules 13.26.1 Dice molecules Company Information 13.26.2 Dice molecules Ankylosing Spondylitis Medication Product Portfolios and Specifications 13.26.3 Dice molecules Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024) 13.26.4 Dice molecules Main Business Overview 13.26.5 Dice molecules Latest Developments 13.27 MSD 13.27.1 MSD Company Information 13.27.2 MSD Ankylosing Spondylitis Medication Product Portfolios and Specifications 13.27.3 MSD Ankylosing Spondylitis Medication Sales, Revenue, Price and Gross Margin (2019-2024) 13.27.4 MSD Main Business Overview 13.27.5 MSD Latest Developments 14 Research Findings and Conclusion
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医薬)の最新刊レポート
LP Information社の医薬品・ヘルスケア分野での最新刊レポート
本レポートと同じKEY WORD(medication)の最新刊レポート
よくあるご質問LP Information社はどのような調査会社ですか?LP Informationは通信、エネルギー、医薬をはじめとする広範な市場の調査とレポート出版を行っている調査会社です。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/21 10:26 156.13 円 165.08 円 200.38 円 |